

Introduction of Opportunity

Hello, I'm Jay Newman, president of Argentech.

The business we're in is marketing and licensing a patented technology for the internal human use of ionic silver, called Opti-Silver. Opti-Silver is an extremely powerful and broad-spectrum antibacterial and antiviral agent, yet it's entirely harmless to humans with normal use. It's the result of more than a million dollars in development and is covered by very strong patent protection.

Benefits

The benefits of this opportunity include:

- The potential for very healthy rewards for your financial contribution, in a way that you can really feel good about
- Potentially revolutionizing the field of antibiotics and antiviral medicine with green technology
- The probability of worldwide distribution within 24 months

Big-picture Potential

Mary Meeker, while head of technology for Morgan Stanley, who's famous for predicting and funding Microsoft, Dell, AOL and Amazon, made the following statement an hour after the press release that announced the creation of Opti-Silver:

"The Opti-Silver technology has the potential to lead to a billion-dollar company and make history changing the world of antibiotics, both from a financial point of view and a humanitarian point of view."

A 2006 article in Chemical and Engineering News, stated, quote:

"With antibiotic resistance on the rise, scientists are turning to silver... to control infection by killing bacteria and viruses... The chief technical officer of Nexxion, who makes ionic silver coatings for catheters, IV needles and other medical devices, has stated, 'To date, no pathogens have been able to survive contact with silver.'"

Revolutionary Green Technology

In November of 2007, a company called Pure Bioscience was granted EPA approval for its surface disinfectant that utilizes a form of ionic silver. The EPA approval allows the company to state in advertising and labeling that it kills strains of SARS, Bird Flu, MRSA, influenza, and a range other pathogens.

Roger Leblanc, Ph.D., former head of the Departments of Chemistry and of Advanced Microscopy at the University of Miami has stated, quote:

"The silver-based surface disinfectant by that other company should cause no concern at all to the makers of Opti-Silver. I don't see any competition with Opti-Silver in terms of efficacy for internal and topical human use."

“No other form of silver that I’m aware of comes even close to the effectiveness of the patented Opti-Silver complex for human use.”

Donald Baird, Ph.D., former head of the Department of Chemistry at Florida Atlantic University, has stated, quote:

“That silver-based surface disinfectant is not even remotely comparable to the Opti-Silver complex for providing a delivery mechanism for silver ions in the body. There is simply no comparison at all.”

““To a chemist, Opti-Silver represents a brilliant chemical formulation that results in a far more efficient delivery mechanism for releasing silver ions in the body than has ever existed before.”

Timothy Kingsbury, a nationally recognized osteopathic physician, after using a professional-line version of the Opti-Silver technology in his practice for four months, made the following statement. Quote:

“Of all my patients whose conditions would not respond to any conventional treatment, the success rate with Opti-Silver has been staggering – well over 80%. I don’t like to use the word miraculous, but I’ve been in practice for twenty years, and when I see something I’ve never seen before, it’s exciting. I don’t know of anything that has a better risk/benefit ratio and effectiveness.”

Strategic Plan

The plan is to take this technology to the mainstream market on a worldwide scale.

The strategic plan for achieving explosive growth was carefully developed. It entails a 3-million-dollar clinical study on the prevention of cold and flu in children, which will be conducted at the Center for Drug Research at University Hospitals in Cleveland. This is the world’s largest clinical research center for pediatric drugs.

The human phase will be preceded by an extensive lab phase to ensure very predictable results.

We’re expecting to see the study funded through tax-free contributions into a 501(c)(3) called the Foundation for Health Research.

The Foundation is run by some of the same people who run the National Health Federation, the oldest and probably most respected health freedom advocacy organization in the world.

Investment bankers, mass-market outlets, and pharmaceutical companies seeking licenses are expected to be lined up around the block once the data is in-hand, which should be within 9 to 12 months after the study is funded. We plan to delay the release of the data to the media until the production and distribution channels are fully in place to meet the avalanche in demand that will expectedly result from the massive media coverage that we anticipate.

Prominent industry leaders have predicted that through this strategy, and within as little as 24 to 36 months, we could end up with revenues rivaling those that otherwise could only be achieved by investing hundreds of millions of dollars in FDA drug approval and by having the prescription drug of choice for the majority of infectious diseases.

Jay Newman Background

Before entering into this field, I had the same attorney and accountant as Steven Jobs of Apple, and had the same two investors looking at funding me who funded his two startups, including Ross Perot. Jobs

and Perot persuaded me to walk away from all that and pursue my passion for natural healing, where they said I'd end up making a world of difference.

Since the introduction of Opti-Silver, I've been interviewed on Good Morning America, NBC TV News and others as the leading expert in the industry.

I'm surrounded by a stellar team of people who are equally committed to the humanitarian implications of this endeavor.

Making it Happen

We're looking for the right kind of supporters to make this happen.

If you're now delightfully surprised how much this does feel good to you, then act on it!

We can make this happen, but only as a team.

For more information, contact me.

Thank you.

Jay Newman
President & CEO
jnewman@argentechinc.com
Office: 954-776-2406
Cell: 954-295-3833